RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Roche Holding AG

A collection of news and information related to Roche Holding AG published by this site and its partners.

Top Roche Holding AG Articles

Displaying items 12-22
  • Bristol-Myers demanda a Merck por patente de inmunoterapia en EEUU

    (Reuters) - La farmacéutica Bristol-Myers Squibb Co presentó una demanda el jueves contra Merck & Co Inc por la supuesta violación de su patente de inmunoterapia. La compañía está buscando una compensación por daños no especificada. La inmunoterapia es...
  • Google's Calico, AbbVie forge deal against diseases of aging

    (Reuters) - U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines. AbbVie...
  • InterMune drug may offer big upside to Roche if aimed at liver

    (Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its...
  • Roche to buy U.S. biotech firm InterMune for $8.3 billion

    Roche to buy U.S. biotech firm InterMune for $8.3 billion
    Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc. for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the treatment of rare or incurable diseases. Roche's efforts to produce successful non-...
  • Roche comprará firma de biotecnología EEUU por 8.300 mlns dlrs

    LONDRES/ZURICH (Reuters) - Roche Holding AG acordó comprar la compañía estadounidense de biotecnología InterMune por 8.300 millones de dólares en efectivo, en la última adquisición multimillonaria de un sector farmacéutico que apuesta cada vez más a la...
  • Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

    Exclusive: U.S. approval of Merck cancer immunotherapy expected soon
    U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation. If approved by the...
  • 'Plantibodies' drugs advance as big pharma stands aside

    LOS ANGELES (Reuters) - Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies. The leading...
  • Gilead says panel rejects Roche's claims on hepatitis C drug

    (Reuters) - Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi. Gilead's shares rose as much as 3 percent in early trading. "While this outcome was widely...
  • Achillion's hepatitis C drug shows promise in trial

    (Reuters) - Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. The mid-stage trial tested Achillion's...
  • Roche to offer $10 billion for rest of Chugai: Bloomberg

    (Reuters) - Roche Holding AG is in talks to buy the almost 40 percent stake in Japan's Chugai Pharmaceutical Co Ltd that it does not already own for about $10 billion, Bloomberg reported, citing people familiar with the matter. A spokeswoman for Roche...
  • Healthcare: A remedy for long-term investors

    CHICAGO (Reuters) - (The opinions expressed here are those of the author, a columnist for Reuters.) For healthcare, gray is the new black. The fastest-growing segment of the global population is aged 60 and over, according to the United Nations...